Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-26), 10-Q (reporting date: 2020-06-27), 10-Q (reporting date: 2020-03-28), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-28), 10-Q (reporting date: 2019-06-29), 10-Q (reporting date: 2019-03-30).
Profitability ratio | Description | The company |
---|---|---|
Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Thermo Fisher Scientific Inc. gross profit margin ratio improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Thermo Fisher Scientific Inc. operating profit margin ratio improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Thermo Fisher Scientific Inc. net profit margin ratio improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Profitability ratio | Description | The company |
---|---|---|
ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Thermo Fisher Scientific Inc. ROE improved from Q2 2023 to Q3 2023 but then deteriorated significantly from Q3 2023 to Q4 2023. |
ROA | A profitability ratio calculated as net income divided by total assets. | Thermo Fisher Scientific Inc. ROA improved from Q2 2023 to Q3 2023 but then deteriorated significantly from Q3 2023 to Q4 2023. |
Gross Profit Margin
Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | Dec 31, 2021 | Oct 2, 2021 | Jul 3, 2021 | Apr 3, 2021 | Dec 31, 2020 | Sep 26, 2020 | Jun 27, 2020 | Mar 28, 2020 | Dec 31, 2019 | Sep 28, 2019 | Jun 29, 2019 | Mar 30, 2019 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Gross profit | 4,393) | 4,316) | 4,251) | 4,140) | 4,606) | 4,302) | 4,599) | 5,464) | 5,254) | 4,651) | 4,524) | 5,209) | 5,556) | 4,331) | 3,377) | 2,740) | 3,035) | 2,763) | 2,823) | 2,707) | ||||||
Revenues | 10,886) | 10,574) | 10,687) | 10,710) | 11,450) | 10,677) | 10,970) | 11,818) | 10,702) | 9,330) | 9,273) | 9,906) | 10,550) | 8,521) | 6,917) | 6,230) | 6,829) | 6,272) | 6,316) | 6,125) | ||||||
Profitability Ratio | ||||||||||||||||||||||||||
Gross profit margin1 | 39.90% | 39.87% | 39.75% | 40.28% | 42.24% | 44.42% | 46.63% | 48.37% | 50.08% | 51.05% | 51.29% | 51.47% | 49.67% | 47.31% | 45.39% | 44.30% | 44.35% | — | — | — | ||||||
Benchmarks | ||||||||||||||||||||||||||
Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||
AbbVie Inc. | 62.42% | 65.76% | 68.91% | 69.43% | 70.00% | 69.62% | 70.48% | 69.53% | 68.96% | 67.72% | 65.62% | 64.82% | 66.41% | 68.74% | 73.56% | 77.43% | 77.64% | — | — | — | ||||||
Amgen Inc. | 68.60% | 72.35% | 72.87% | 73.65% | 74.17% | 73.99% | 74.00% | 73.30% | 73.44% | 74.00% | 73.97% | 74.37% | 74.59% | 75.55% | 77.15% | 78.90% | 80.38% | — | — | — | ||||||
Bristol-Myers Squibb Co. | 76.24% | 76.54% | 77.01% | 77.68% | 78.04% | 78.82% | 79.13% | 79.62% | 78.57% | 76.92% | 75.88% | 74.42% | 72.31% | 71.18% | 69.47% | 68.02% | 69.10% | — | — | — | ||||||
Eli Lilly & Co. | 79.25% | 78.67% | 77.77% | 77.67% | 76.77% | 75.61% | 75.98% | 74.40% | 74.18% | 74.85% | 74.27% | 75.88% | 77.66% | 78.26% | 78.67% | 79.22% | 78.85% | — | — | — | ||||||
Gilead Sciences Inc. | 75.87% | 78.66% | 79.27% | 78.94% | 79.03% | 74.31% | 75.30% | 75.50% | 75.56% | 80.23% | 79.90% | 80.32% | 81.23% | 78.72% | 78.25% | 79.06% | 78.86% | — | — | — | ||||||
Johnson & Johnson | 68.82% | 67.51% | 67.09% | 66.88% | 67.26% | 67.43% | 67.86% | 67.97% | 68.16% | 67.51% | 67.00% | 66.24% | 65.58% | 65.68% | 65.66% | 66.15% | 66.42% | — | — | — | ||||||
Merck & Co. Inc. | 73.17% | 72.86% | 72.96% | 72.43% | 70.63% | 70.49% | 70.41% | 70.72% | 72.02% | 67.95% | 67.48% | 66.99% | 67.74% | 71.23% | 70.06% | 70.11% | 69.87% | — | — | — | ||||||
Pfizer Inc. | 57.34% | 60.55% | 69.42% | 68.54% | 65.77% | 65.53% | 62.18% | 60.35% | 62.08% | 65.28% | 70.96% | 76.46% | 79.26% | 80.47% | 80.19% | 80.03% | 80.25% | — | — | — | ||||||
Regeneron Pharmaceuticals Inc. | 86.16% | 85.96% | 86.42% | 86.96% | 87.18% | 85.39% | 84.97% | 84.65% | 84.83% | 86.65% | 86.85% | 86.84% | 86.82% | 87.98% | 88.21% | 89.72% | 90.05% | — | — | — | ||||||
Vertex Pharmaceuticals Inc. | 87.21% | 87.80% | 87.92% | 88.04% | 87.90% | 88.00% | 88.13% | 87.95% | 88.06% | 87.94% | 87.89% | 88.06% | 88.14% | 88.01% | 87.71% | 87.24% | 86.84% | — | — | — |
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-26), 10-Q (reporting date: 2020-06-27), 10-Q (reporting date: 2020-03-28), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-28), 10-Q (reporting date: 2019-06-29), 10-Q (reporting date: 2019-03-30).
1 Q4 2023 Calculation
Gross profit margin = 100
× (Gross profitQ4 2023
+ Gross profitQ3 2023
+ Gross profitQ2 2023
+ Gross profitQ1 2023)
÷ (RevenuesQ4 2023
+ RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023)
= 100 × (4,393 + 4,316 + 4,251 + 4,140)
÷ (10,886 + 10,574 + 10,687 + 10,710)
= 39.90%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Thermo Fisher Scientific Inc. gross profit margin ratio improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Operating Profit Margin
Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | Dec 31, 2021 | Oct 2, 2021 | Jul 3, 2021 | Apr 3, 2021 | Dec 31, 2020 | Sep 26, 2020 | Jun 27, 2020 | Mar 28, 2020 | Dec 31, 2019 | Sep 28, 2019 | Jun 29, 2019 | Mar 30, 2019 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Operating income | 1,854) | 1,864) | 1,578) | 1,563) | 1,861) | 1,710) | 2,001) | 2,821) | 2,538) | 2,278) | 2,163) | 3,049) | 3,071) | 2,426) | 1,391) | 906) | 1,232) | 946) | 1,496) | 920) | ||||||
Revenues | 10,886) | 10,574) | 10,687) | 10,710) | 11,450) | 10,677) | 10,970) | 11,818) | 10,702) | 9,330) | 9,273) | 9,906) | 10,550) | 8,521) | 6,917) | 6,230) | 6,829) | 6,272) | 6,316) | 6,125) | ||||||
Profitability Ratio | ||||||||||||||||||||||||||
Operating profit margin1 | 16.00% | 15.81% | 15.42% | 16.29% | 18.69% | 20.54% | 22.51% | 23.83% | 25.57% | 27.04% | 28.00% | 27.68% | 24.19% | 20.90% | 17.05% | 17.86% | 17.99% | — | — | — | ||||||
Benchmarks | ||||||||||||||||||||||||||
Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||
AbbVie Inc. | 23.49% | 27.32% | 31.03% | 28.49% | 31.21% | 30.59% | 30.33% | 32.68% | 31.89% | 30.09% | 28.95% | 23.63% | 24.81% | 28.45% | 30.17% | 39.86% | 39.03% | — | — | — | ||||||
Amgen Inc. | 29.35% | 34.55% | 37.50% | 36.07% | 38.57% | 39.31% | 38.04% | 32.78% | 31.44% | 30.14% | 30.72% | 37.23% | 37.70% | 38.59% | 39.76% | 41.89% | 43.57% | — | — | — | ||||||
Bristol-Myers Squibb Co. | 16.18% | 16.96% | 17.29% | 18.13% | 17.96% | 19.04% | 18.19% | 16.79% | 15.91% | -15.73% | -17.02% | -19.19% | -21.60% | 9.27% | 11.67% | 16.30% | 22.62% | — | — | — | ||||||
Eli Lilly & Co. | 18.92% | 18.42% | 24.17% | 22.45% | 24.97% | 24.65% | 25.50% | 25.94% | 22.45% | 23.17% | 21.81% | 22.06% | 24.69% | 23.55% | 24.48% | 25.64% | 22.29% | — | — | — | ||||||
Gilead Sciences Inc. | 28.24% | 30.37% | 31.18% | 33.03% | 27.17% | 22.39% | 25.78% | 26.56% | 36.72% | 42.79% | 37.20% | 18.07% | 16.72% | 11.01% | -4.40% | 19.89% | 19.38% | — | — | — | ||||||
Johnson & Johnson | 24.90% | 25.19% | 25.26% | 25.04% | 24.63% | 23.89% | 23.47% | 23.76% | 24.95% | 24.69% | 25.23% | 24.10% | 23.60% | 24.30% | 24.64% | 25.62% | 24.15% | — | — | — | ||||||
Merck & Co. Inc. | 3.92% | 13.08% | 10.34% | 27.85% | 30.27% | 30.66% | 33.04% | 28.85% | 25.74% | 14.07% | 10.64% | 14.02% | 16.47% | 26.87% | 25.40% | 25.49% | 24.77% | — | — | — | ||||||
Pfizer Inc. | 0.38% | 13.44% | 27.69% | 34.30% | 34.83% | 33.59% | 30.37% | 26.12% | 23.91% | 24.67% | 24.12% | 21.20% | 19.47% | 21.17% | 21.17% | 24.20% | 25.46% | — | — | — | ||||||
Regeneron Pharmaceuticals Inc. | 30.85% | 32.23% | 34.20% | 35.79% | 38.93% | 45.45% | 48.19% | 55.08% | 55.67% | 55.19% | 53.94% | 43.37% | 42.09% | 37.43% | 34.64% | 30.45% | 28.10% | — | — | — | ||||||
Vertex Pharmaceuticals Inc. | 38.83% | 40.16% | 41.72% | 43.93% | 48.23% | 47.72% | 48.85% | 36.93% | 36.73% | 37.17% | 33.93% | 47.14% | 46.03% | 44.43% | 38.67% | 34.05% | 28.77% | — | — | — |
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-26), 10-Q (reporting date: 2020-06-27), 10-Q (reporting date: 2020-03-28), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-28), 10-Q (reporting date: 2019-06-29), 10-Q (reporting date: 2019-03-30).
1 Q4 2023 Calculation
Operating profit margin = 100
× (Operating incomeQ4 2023
+ Operating incomeQ3 2023
+ Operating incomeQ2 2023
+ Operating incomeQ1 2023)
÷ (RevenuesQ4 2023
+ RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023)
= 100 × (1,854 + 1,864 + 1,578 + 1,563)
÷ (10,886 + 10,574 + 10,687 + 10,710)
= 16.00%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Thermo Fisher Scientific Inc. operating profit margin ratio improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Net Profit Margin
Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | Dec 31, 2021 | Oct 2, 2021 | Jul 3, 2021 | Apr 3, 2021 | Dec 31, 2020 | Sep 26, 2020 | Jun 27, 2020 | Mar 28, 2020 | Dec 31, 2019 | Sep 28, 2019 | Jun 29, 2019 | Mar 30, 2019 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Net income attributable to Thermo Fisher Scientific Inc. | 1,630) | 1,715) | 1,361) | 1,289) | 1,576) | 1,495) | 1,664) | 2,215) | 1,658) | 1,902) | 1,828) | 2,337) | 2,498) | 1,933) | 1,156) | 788) | 1,002) | 760) | 1,119) | 815) | ||||||
Revenues | 10,886) | 10,574) | 10,687) | 10,710) | 11,450) | 10,677) | 10,970) | 11,818) | 10,702) | 9,330) | 9,273) | 9,906) | 10,550) | 8,521) | 6,917) | 6,230) | 6,829) | 6,272) | 6,316) | 6,125) | ||||||
Profitability Ratio | ||||||||||||||||||||||||||
Net profit margin1 | 13.99% | 13.68% | 13.14% | 13.75% | 15.47% | 15.92% | 17.37% | 18.49% | 19.70% | 21.93% | 22.47% | 22.08% | 19.79% | 17.12% | 14.12% | 14.31% | 14.47% | — | — | — | ||||||
Benchmarks | ||||||||||||||||||||||||||
Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||
AbbVie Inc. | 8.95% | 11.81% | 15.50% | 13.37% | 20.39% | 23.19% | 22.04% | 22.00% | 20.54% | 13.66% | 12.40% | 10.28% | 10.08% | 18.16% | 19.20% | 24.77% | 23.69% | — | — | — | ||||||
Amgen Inc. | 24.96% | 29.52% | 31.52% | 31.77% | 26.42% | 27.88% | 26.73% | 23.42% | 24.25% | 23.03% | 23.80% | 29.60% | 29.97% | 30.91% | 31.53% | 33.64% | 35.32% | — | — | — | ||||||
Bristol-Myers Squibb Co. | 17.83% | 18.44% | 17.62% | 15.95% | 13.71% | 14.29% | 14.04% | 13.31% | 15.08% | -11.89% | -11.44% | -14.53% | -21.20% | -0.11% | -1.61% | 3.08% | 13.15% | — | — | — | ||||||
Eli Lilly & Co. | 15.36% | 15.55% | 22.01% | 20.54% | 21.88% | 20.63% | 19.58% | 20.90% | 19.71% | 21.52% | 22.71% | 23.91% | 25.24% | 24.01% | 24.48% | 23.97% | 37.27% | — | — | — | ||||||
Gilead Sciences Inc. | 21.03% | 21.60% | 20.18% | 20.87% | 17.02% | 12.44% | 15.22% | 16.60% | 23.05% | 27.21% | 19.62% | 1.19% | 0.51% | 5.56% | -1.18% | 22.17% | 24.35% | — | — | — | ||||||
Johnson & Johnson | 41.28% | 36.32% | 13.35% | 13.22% | 18.90% | 19.95% | 19.21% | 20.90% | 22.26% | 19.55% | 19.92% | 17.95% | 17.82% | 21.01% | 18.86% | 20.75% | 18.42% | — | — | — | ||||||
Merck & Co. Inc. | 0.61% | 7.77% | 5.34% | 22.52% | 24.49% | 25.88% | 29.00% | 26.27% | 26.79% | 15.09% | 11.83% | 15.09% | 14.72% | 24.33% | 22.20% | 21.10% | 21.01% | — | — | — | ||||||
Pfizer Inc. | 3.62% | 15.29% | 27.55% | 31.25% | 31.27% | 29.81% | 28.94% | 27.01% | 27.04% | 28.77% | 23.86% | 24.03% | 22.95% | 18.59% | 31.31% | 32.32% | 31.45% | — | — | — | ||||||
Regeneron Pharmaceuticals Inc. | 30.14% | 30.47% | 33.93% | 33.81% | 35.64% | 39.17% | 39.97% | 48.06% | 50.25% | 51.65% | 50.11% | 43.53% | 41.35% | 38.28% | 37.30% | 28.56% | 26.91% | — | — | — | ||||||
Vertex Pharmaceuticals Inc. | 36.68% | 35.94% | 35.40% | 35.40% | 37.20% | 37.62% | 38.26% | 30.84% | 30.92% | 30.52% | 29.80% | 43.06% | 43.70% | 44.91% | 38.51% | 31.35% | 28.27% | — | — | — |
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-26), 10-Q (reporting date: 2020-06-27), 10-Q (reporting date: 2020-03-28), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-28), 10-Q (reporting date: 2019-06-29), 10-Q (reporting date: 2019-03-30).
1 Q4 2023 Calculation
Net profit margin = 100
× (Net income attributable to Thermo Fisher Scientific Inc.Q4 2023
+ Net income attributable to Thermo Fisher Scientific Inc.Q3 2023
+ Net income attributable to Thermo Fisher Scientific Inc.Q2 2023
+ Net income attributable to Thermo Fisher Scientific Inc.Q1 2023)
÷ (RevenuesQ4 2023
+ RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023)
= 100 × (1,630 + 1,715 + 1,361 + 1,289)
÷ (10,886 + 10,574 + 10,687 + 10,710)
= 13.99%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Thermo Fisher Scientific Inc. net profit margin ratio improved from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023. |
Return on Equity (ROE)
Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | Dec 31, 2021 | Oct 2, 2021 | Jul 3, 2021 | Apr 3, 2021 | Dec 31, 2020 | Sep 26, 2020 | Jun 27, 2020 | Mar 28, 2020 | Dec 31, 2019 | Sep 28, 2019 | Jun 29, 2019 | Mar 30, 2019 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Net income attributable to Thermo Fisher Scientific Inc. | 1,630) | 1,715) | 1,361) | 1,289) | 1,576) | 1,495) | 1,664) | 2,215) | 1,658) | 1,902) | 1,828) | 2,337) | 2,498) | 1,933) | 1,156) | 788) | 1,002) | 760) | 1,119) | 815) | ||||||
Total Thermo Fisher Scientific Inc. shareholders’ equity | 46,735) | 45,328) | 43,752) | 42,257) | 43,978) | 43,549) | 42,293) | 40,956) | 40,793) | 38,710) | 36,854) | 35,058) | 34,507) | 31,824) | 29,875) | 28,559) | 29,675) | 29,355) | 28,729) | 27,693) | ||||||
Profitability Ratio | ||||||||||||||||||||||||||
ROE1 | 12.83% | 13.11% | 13.08% | 14.26% | 15.80% | 16.15% | 17.59% | 18.56% | 18.94% | 22.13% | 23.32% | 22.60% | 18.47% | 15.33% | 12.41% | 12.85% | 12.45% | — | — | — | ||||||
Benchmarks | ||||||||||||||||||||||||||
ROE, Competitors2 | ||||||||||||||||||||||||||
AbbVie Inc. | 46.94% | 53.86% | 67.50% | 57.14% | 68.60% | 83.83% | 86.24% | 76.64% | 74.91% | 55.60% | 53.01% | 37.63% | 35.30% | 48.34% | 47.30% | — | — | — | — | — | ||||||
Amgen Inc. | 107.78% | 98.82% | 117.67% | 148.04% | 178.97% | 187.11% | 271.85% | 624.78% | 87.96% | 68.26% | 69.67% | 75.91% | 77.20% | 67.09% | 68.48% | 80.92% | 81.07% | — | — | — | ||||||
Bristol-Myers Squibb Co. | 27.27% | 28.57% | 24.91% | 22.97% | 20.37% | 20.44% | 20.30% | 19.79% | 19.46% | -14.52% | -13.80% | -16.54% | -23.84% | -0.09% | -1.15% | 1.91% | 6.66% | — | — | — | ||||||
Eli Lilly & Co. | 48.65% | 44.46% | 58.73% | 50.82% | 58.64% | 59.91% | 66.61% | 65.69% | 62.16% | 76.99% | 94.20% | 88.31% | 109.79% | 115.45% | 137.26% | 179.72% | 319.09% | — | — | — | ||||||
Gilead Sciences Inc. | 24.81% | 26.33% | 25.92% | 26.59% | 21.62% | 15.82% | 20.44% | 22.66% | 29.55% | 34.44% | 26.20% | 1.59% | 0.68% | 7.27% | -1.43% | 22.49% | 23.91% | — | — | — | ||||||
Johnson & Johnson | 51.11% | 48.61% | 17.37% | 17.95% | 23.36% | 25.68% | 24.05% | 26.54% | 28.20% | 25.44% | 25.53% | 22.96% | 23.25% | 26.35% | 24.11% | 28.01% | 25.42% | — | — | — | ||||||
Merck & Co. Inc. | 0.97% | 11.17% | 8.04% | 27.82% | 31.57% | 34.32% | 38.34% | 34.68% | 34.17% | 20.10% | 16.73% | 26.08% | 27.91% | 39.47% | 37.91% | 38.72% | 37.99% | — | — | — | ||||||
Pfizer Inc. | 2.38% | 10.81% | 21.68% | 28.77% | 32.79% | 32.14% | 33.61% | 30.29% | 28.47% | 26.28% | 18.86% | 16.23% | 15.21% | 12.22% | 22.05% | 24.21% | 25.77% | — | — | — | ||||||
Regeneron Pharmaceuticals Inc. | 15.22% | 16.03% | 17.90% | 17.80% | 19.14% | 25.05% | 27.49% | 39.84% | 43.03% | 40.53% | 41.02% | 33.43% | 31.86% | 31.17% | 32.94% | 18.79% | 19.08% | — | — | — | ||||||
Vertex Pharmaceuticals Inc. | 20.59% | 21.01% | 21.75% | 22.59% | 23.88% | 25.12% | 26.77% | 22.47% | 23.19% | 22.83% | 21.66% | 30.76% | 31.22% | 33.08% | 27.67% | 23.38% | 19.34% | — | — | — |
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-26), 10-Q (reporting date: 2020-06-27), 10-Q (reporting date: 2020-03-28), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-28), 10-Q (reporting date: 2019-06-29), 10-Q (reporting date: 2019-03-30).
1 Q4 2023 Calculation
ROE = 100
× (Net income attributable to Thermo Fisher Scientific Inc.Q4 2023
+ Net income attributable to Thermo Fisher Scientific Inc.Q3 2023
+ Net income attributable to Thermo Fisher Scientific Inc.Q2 2023
+ Net income attributable to Thermo Fisher Scientific Inc.Q1 2023)
÷ Total Thermo Fisher Scientific Inc. shareholders’ equity
= 100 × (1,630 + 1,715 + 1,361 + 1,289)
÷ 46,735 = 12.83%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Thermo Fisher Scientific Inc. ROE improved from Q2 2023 to Q3 2023 but then deteriorated significantly from Q3 2023 to Q4 2023. |
Return on Assets (ROA)
Dec 31, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Oct 1, 2022 | Jul 2, 2022 | Apr 2, 2022 | Dec 31, 2021 | Oct 2, 2021 | Jul 3, 2021 | Apr 3, 2021 | Dec 31, 2020 | Sep 26, 2020 | Jun 27, 2020 | Mar 28, 2020 | Dec 31, 2019 | Sep 28, 2019 | Jun 29, 2019 | Mar 30, 2019 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Net income attributable to Thermo Fisher Scientific Inc. | 1,630) | 1,715) | 1,361) | 1,289) | 1,576) | 1,495) | 1,664) | 2,215) | 1,658) | 1,902) | 1,828) | 2,337) | 2,498) | 1,933) | 1,156) | 788) | 1,002) | 760) | 1,119) | 815) | ||||||
Total assets | 98,726) | 97,057) | 94,105) | 94,658) | 97,154) | 90,536) | 90,579) | 92,747) | 95,123) | 73,600) | 67,698) | 65,931) | 69,052) | 64,061) | 61,593) | 58,688) | 58,381) | 56,729) | 57,970) | 55,596) | ||||||
Profitability Ratio | ||||||||||||||||||||||||||
ROA1 | 6.07% | 6.12% | 6.08% | 6.36% | 7.15% | 7.77% | 8.21% | 8.20% | 8.12% | 11.64% | 12.70% | 12.02% | 9.23% | 7.62% | 6.02% | 6.25% | 6.33% | — | — | — | ||||||
Benchmarks | ||||||||||||||||||||||||||
ROA, Competitors2 | ||||||||||||||||||||||||||
AbbVie Inc. | 3.61% | 4.78% | 6.42% | 5.64% | 8.53% | 9.49% | 8.83% | 8.71% | 7.88% | 5.06% | 4.50% | 3.43% | 3.07% | 4.93% | 4.65% | 9.25% | 8.84% | — | — | — | ||||||
Amgen Inc. | 6.91% | 8.36% | 8.84% | 8.92% | 10.06% | 10.73% | 11.09% | 9.67% | 9.63% | 8.63% | 9.61% | 11.33% | 11.54% | 11.37% | 11.23% | 12.45% | 13.13% | — | — | — | ||||||
Bristol-Myers Squibb Co. | 8.43% | 9.08% | 8.52% | 7.75% | 6.53% | 6.80% | 6.59% | 6.07% | 6.40% | -4.87% | -4.58% | -5.53% | -7.61% | -0.04% | -0.44% | 0.74% | 2.65% | — | — | — | ||||||
Eli Lilly & Co. | 8.19% | 8.61% | 11.85% | 10.70% | 12.62% | 12.71% | 12.09% | 13.06% | 11.44% | 12.39% | 12.70% | 13.01% | 13.28% | 12.68% | 13.39% | 13.46% | 21.17% | — | — | — | ||||||
Gilead Sciences Inc. | 9.12% | 9.42% | 8.80% | 9.02% | 7.27% | 5.33% | 6.58% | 7.16% | 9.16% | 11.02% | 7.59% | 0.45% | 0.18% | 2.08% | -0.46% | 8.31% | 8.74% | — | — | — | ||||||
Johnson & Johnson | 20.98% | 20.85% | 6.81% | 6.49% | 9.57% | 10.94% | 10.33% | 11.12% | 11.47% | 9.98% | 10.07% | 8.76% | 8.41% | 9.95% | 9.59% | 11.07% | 9.59% | — | — | — | ||||||
Merck & Co. Inc. | 0.34% | 4.32% | 2.98% | 12.09% | 13.30% | 14.25% | 15.48% | 13.29% | 12.35% | 7.70% | 6.14% | 7.73% | 7.72% | 12.83% | 11.56% | 11.95% | 11.66% | — | — | — | ||||||
Pfizer Inc. | 0.94% | 4.87% | 9.75% | 14.85% | 15.91% | 15.32% | 15.01% | 13.58% | 12.11% | 11.10% | 7.78% | 7.01% | 6.23% | 4.46% | 7.97% | 9.47% | 9.72% | — | — | — | ||||||
Regeneron Pharmaceuticals Inc. | 11.95% | 12.41% | 14.02% | 13.91% | 14.85% | 19.40% | 20.90% | 30.11% | 31.75% | 29.55% | 28.88% | 22.53% | 20.47% | 19.62% | 20.68% | 14.46% | 14.29% | — | — | — | ||||||
Vertex Pharmaceuticals Inc. | 15.92% | 15.97% | 16.54% | 17.18% | 18.30% | 19.59% | 20.50% | 17.19% | 17.44% | 17.25% | 16.30% | 22.80% | 23.07% | 23.81% | 20.37% | 16.99% | 14.15% | — | — | — |
Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-07-01), 10-Q (reporting date: 2023-04-01), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-01), 10-Q (reporting date: 2022-07-02), 10-Q (reporting date: 2022-04-02), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-02), 10-Q (reporting date: 2021-07-03), 10-Q (reporting date: 2021-04-03), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-26), 10-Q (reporting date: 2020-06-27), 10-Q (reporting date: 2020-03-28), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-28), 10-Q (reporting date: 2019-06-29), 10-Q (reporting date: 2019-03-30).
1 Q4 2023 Calculation
ROA = 100
× (Net income attributable to Thermo Fisher Scientific Inc.Q4 2023
+ Net income attributable to Thermo Fisher Scientific Inc.Q3 2023
+ Net income attributable to Thermo Fisher Scientific Inc.Q2 2023
+ Net income attributable to Thermo Fisher Scientific Inc.Q1 2023)
÷ Total assets
= 100 × (1,630 + 1,715 + 1,361 + 1,289)
÷ 98,726 = 6.07%
2 Click competitor name to see calculations.
Profitability ratio | Description | The company |
---|---|---|
ROA | A profitability ratio calculated as net income divided by total assets. | Thermo Fisher Scientific Inc. ROA improved from Q2 2023 to Q3 2023 but then deteriorated significantly from Q3 2023 to Q4 2023. |